Optimist Retirement Group LLC reduced its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 10.6% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 23,304 shares of the biopharmaceutical company's stock after selling 2,777 shares during the quarter. Gilead Sciences accounts for 1.3% of Optimist Retirement Group LLC's holdings, making the stock its 12th biggest holding. Optimist Retirement Group LLC's holdings in Gilead Sciences were worth $2,611,000 as of its most recent filing with the SEC.
Other large investors also recently modified their holdings of the company. Smallwood Wealth Investment Management LLC bought a new position in Gilead Sciences in the first quarter valued at about $25,000. Goodman Advisory Group LLC bought a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC raised its position in shares of Gilead Sciences by 158.8% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock worth $33,000 after acquiring an additional 216 shares during the last quarter. Core Alternative Capital raised its position in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 241 shares during the last quarter. Finally, Lee Danner & Bass Inc. bought a new position in shares of Gilead Sciences during the fourth quarter worth about $41,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In related news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total transaction of $333,090.00. Following the completion of the transaction, the insider owned 117,168 shares of the company's stock, valued at $13,009,163.04. This trade represents a 2.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Andrew D. Dickinson sold 2,500 shares of the firm's stock in a transaction that occurred on Tuesday, July 15th. The shares were sold at an average price of $111.03, for a total value of $277,575.00. Following the transaction, the chief financial officer directly owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. This trade represents a 1.51% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 72,000 shares of company stock worth $7,844,775. Corporate insiders own 0.27% of the company's stock.
Wall Street Analyst Weigh In
A number of equities analysts have recently issued reports on GILD shares. Morgan Stanley raised their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald initiated coverage on Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fourteen have issued a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $111.38.
Check Out Our Latest Stock Report on Gilead Sciences
Gilead Sciences Price Performance
Shares of NASDAQ GILD opened at $108.22 on Friday. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The firm has a market capitalization of $134.62 billion, a P/E ratio of 22.78, a P/E/G ratio of 0.70 and a beta of 0.29. The stock's 50-day simple moving average is $108.81 and its two-hundred day simple moving average is $105.26. Gilead Sciences, Inc. has a twelve month low of $70.78 and a twelve month high of $119.96.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. During the same period in the prior year, the company earned ($1.32) EPS. The company's revenue was down .3% on a year-over-year basis. As a group, equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.92%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
